Evidence map›Paper›PMID 36455419›Full record

ArticleThe Journal of surgical research2023

Assessment of Attitudes Toward Initiation of Immediate Adjuvant Chemotherapy for Colon Cancer.

Andrea M Mesiti, Julianna Brouwer, Mehraneh D Jafari, Yuqing Qiu, Lari Wenzel, Joseph Carmichael, Chelsea McKinney, Jason A Zell, Alessio Pigazzi

Abstract read
In one paragraph

Article in The Journal of surgical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrea M MesitiWeill Cornell Medical College, Surgery, New York, New York. Electronic address: anm9360@med.cornell.edu.
Julianna BrouwerWeill Cornell Medical College, Surgery, New York, New York.
Mehraneh D JafariWeill Cornell Medical College, Surgery, New York, New York.
Yuqing QiuDepartment of Population Health Sciences, New York, New York.
Lari WenzelUC Irvine Department of Medicine, Orange, California; Chao Family Comprehensive Cancer Center, UC Irvine Medical Center 101 The City Drive South, Orange, California.
Joseph CarmichaelUniversity Of California - Irvine, Dept of Surgery, Orange, California.
Chelsea McKinneyChao Family Comprehensive Cancer Center, UC Irvine Medical Center 101 The City Drive South, Orange, California.
Jason A ZellUC Irvine Department of Medicine, Orange, California.
Alessio PigazziWeill Cornell Medical College, Surgery, New York, New York.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Christine Hui · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

introductionEarly initiation of chemotherapy after surgery for colon cancer has survival benefits. Immediate adjuvant chemotherapy (IAC) involves giving chemotherapy during surgical resection and immediately postoperatively. This novel approach has been shown to be safe, eliminating delays in adjuvant treatment that could increase the risk of micro-metastatic spread. The aim of this study was to assess the willingness of the general public to accept IAC. MATERIALS AND

methodsBetween March and April 2021, 800 telephone interviews were conducted with a sample of adult New York State residents. The Survey Research Institute of Cornell University conducted all surveys. Kruskal-Wallis, chi-squared, and Fisher's tests were conducted using R 4.0.2.

resultsThree scenarios were presented: (1) receiving IAC resulting in improved survival and quality of life, (2) finishing chemotherapy earlier without survival impact, and (3) finishing chemotherapy earlier but with possible side effects. Respondents with higher education were more likely to accept (1) & (2), males were more likely to accept (2) & (3), higher income respondents were more likely to accept (1) & (3), and those with more work hours were more likely to accept (2). Lastly, 16% responded they would be very or extremely likely, and 52% respondents would be somewhat likely or likely to accept intraoperative chemotherapy, even if it may not be necessary.

conclusionsRespondents were likely to accept IAC if offered. Given the known risk of delayed adjuvant chemotherapy (AC) in colon cancer, further research is warranted to determine the survival and quality of life (QOL) benefits of IAC.

Indexed as

Colonic NeoplasmsQuality of LifeAdjuvants, ImmunologicAdultChemotherapy, AdjuvantHumansMaleNeoplasm StagingAdjuvants, ImmunologicAdjuvant chemotherapyColon cancerColon resectionEarly adjuvant chemotherapyPerioperative phase of care

Identifiers

PMID36455419
PMCPMC10681158

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.